Sunovion Pharmaceuticals, Marlborough.
J Clin Psychopharmacol. 2020 Sep/Oct;40(5):491-494. doi: 10.1097/JCP.0000000000001261.
A new mood rating scale for mixed states of depression along with manic-like excitatory symptoms, the Koukopoulos Mixed Depression Rating Scale (KMDRS), was assessed in a post hoc analysis of a randomized clinical trial of lurasidone versus placebo in major depressive disorder (MDD) with mixed features.
The KMDRS was compared with the Montgomery Asberg Depression Rating Scale (MADRS) and the Young Mania Rating Scale (YMRS). Item weighting was performed and compared with an original KMDRS validation data set. Weighting was used to provide imputed KMDRS scores in the lurasidone study, based on observed MADRS and YMRS scores.
Standardized effect sizes were larger for MADRS (0.61) and YMRS (0.79) than for KMDRS (0.44, Cohen d).
This analysis did not find that the KMDRS produced a larger effect size than the MADRS in Diagnostic and Statistical Manual for Mental Disorder-5 (DSM-5) defined MDD with mixed features. The lower utility of KMDRS may be due to the imputed nature of this analysis, or also to the DSM-5 defined patient population, which may reflect mixed hypomania rather than mixed depression.
一种新的混合抑郁状态情绪评定量表,即 Koukopoulos 混合抑郁评定量表(KMDRS),在伴有躁狂样兴奋症状的混合特征重度抑郁症(MDD)的一项随机临床试验中,作为事后分析,对其进行了评估。
KMDRS 与蒙哥马利抑郁评定量表(MADRS)和 Young 躁狂评定量表(YMRS)进行了比较。对项目进行了加权,并与原始的 KMDRS 验证数据集进行了比较。根据观察到的 MADRS 和 YMRS 评分,加权用于提供 lurasidone 研究中 KMDRS 的估算得分。
MADRS(0.61)和 YMRS(0.79)的标准化效应量大于 KMDRS(0.44,Cohen d)。
本分析并未发现 KMDRS 在 DSM-5 定义的伴有混合特征的 MDD 中比 MADRS 产生更大的效应量。KMDRS 的效用较低可能是由于此分析的推断性质,或者也可能是由于 DSM-5 定义的患者人群,该人群可能反映的是混合轻躁狂,而不是混合性抑郁。